ORIENTBIO Inc. Audit Report Review: Net Loss and Negative Retained Earnings Despite Stable Debt Ratio and Minor Treasury Stock Disposal


  • ORIENTBIO Inc.'s 69th audit report reveals a net loss of 4.57 billion KRW, turning retained earnings negative to 0.52 billion KRW. The operating loss widened to 4.13 billion KRW while revenue remained flat at 29.75 billion KRW.
  • The company disposed of 14,879 treasury shares, generating 9.3 million KRW in cash inflow, a negligible amount relative to total outstanding shares. Total equity decreased to 68.5 billion KRW.
  • Financial soundness indicators show a low debt ratio of 19% and a net cash position of 5.83 billion KRW. However, a lawsuit from the Korea Research Institute of Bioscience and Biotechnology claiming 0.34 billion KRW has been filed, posing a potential contingent liability.
  • [AI Summary]ORIENTBIO Inc. faces continued operating losses and negative retained earnings, but maintains a debt-free capital structure with a low debt ratio. The absence of capital events suggests limited short-term impact on stock price, though litigation risk warrants monitoring.

KOSPI Filing Information


  • Annual Report (2026.03)
  • Company: ORIENTBIO (002630)
  • Submission: ORIENTBIO Inc.

  • Shares: 59,291,502
  • Price: 902 KRW
  • Market Cap: 53.5 B KRW